PALO ALTO, Calif., Sept. 01, 2016 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco.
Eiger BioPharmaceuticals management is scheduled to present on Wednesday, September 7 at 1:30 p.m. Pacific time, with one-on-one meetings held throughout the conference.
The presentation will be webcast live and available for replay in the Investor Relations section of Eiger BioPharmaceuticals website at www.eigerbio.com or on the Gateway Conference website at www.gateway-conference.com/presenters.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].
About the Gateway Conference
The 5th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About Eiger BioPharmaceuticals
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The Company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Contact:
Jim Shaffer
[email protected]
(919) 345-4256


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Instagram Outage Disrupts Thousands of U.S. Users
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



